| 000 | 01206 a2200337 4500 | ||
|---|---|---|---|
| 005 | 20250517144456.0 | ||
| 264 | 0 | _c20170504 | |
| 008 | 201705s 0 0 eng d | ||
| 022 | _a2049-632X | ||
| 024 | 7 |
_a10.1093/femspd/ftx025 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aFindlow, Jamie | |
| 245 | 0 | 0 |
_aDoes post-implementation vaccine effectiveness data support pre-implementation predictions of 4CMenB utility? _h[electronic resource] |
| 260 |
_bPathogens and disease _cMar 2017 |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntigens, Bacterial _ximmunology |
| 650 | 0 | 4 | _aCost-Benefit Analysis |
| 650 | 0 | 4 |
_aCross Reactions _ximmunology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImmunization |
| 650 | 0 | 4 |
_aMeningococcal Infections _xepidemiology |
| 650 | 0 | 4 |
_aMeningococcal Vaccines _ximmunology |
| 650 | 0 | 4 |
_aNeisseria meningitidis _xclassification |
| 650 | 0 | 4 | _aOutcome Assessment, Health Care |
| 650 | 0 | 4 | _aPopulation Surveillance |
| 650 | 0 | 4 | _aPrognosis |
| 700 | 1 | _aBorrow, Ray | |
| 773 | 0 |
_tPathogens and disease _gvol. 75 _gno. 2 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1093/femspd/ftx025 _zAvailable from publisher's website |
| 999 |
_c27007797 _d27007797 |
||